Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

This is a randomized, controlled, single-center clinical study to evaluate AK104 in FIGO 2018 stage III-IV ovarian cancer subjects who were assessed to be at high perioperative risk and/or unable to achieve R0 resection prior to initial treatment. The efficacy and safety of neoadjuvant therapy with intravenous infusion combined with chemotherapy compared with chemotherapy alone.

NCT Number	NCT06542549
Lead Sponsor	Anhui Provincial Hospital
Conditions	Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, Safety
Enrollment	100 participants
Start Date	2024-10-01
Primary Completion	2027-10-31 (estimated)
Study Completion	2030-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-07